# KSQ-004EX

Source: https://onco.cc/drugs/ksq-004ex/  
OnCo record `ksq-004ex` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

KSQ-004EX is an experimental engineered immune-cell therapy from KSQ Therapeutics, in phase 1 trials for selected advanced solid tumours.

## Summary

KSQ-004EX is an autologous CRISPR/Cas9-engineered tumour-infiltrating lymphocyte (eTIL) therapy from KSQ Therapeutics. Tumour-infiltrating lymphocytes with both the Regnase-1 and SOCS1 genes switched off by CRISPR/Cas9. Its phase 1/2 study (NCT06598371) is recruiting; the company's pipeline lists melanoma, lung, head and neck, colorectal, pancreatic and cervical cancers. OnCo has no Regnase-1 target record. Whether it works in people has not been established.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Code: KSQ-004EX
- Modality: Autologous CRISPR/Cas9-engineered tumour-infiltrating lymphocyte (eTIL) therapy
- Mechanism: Tumour-infiltrating lymphocytes with both the Regnase-1 and SOCS1 genes switched off by CRISPR/Cas9.

## Sources

- KSQ Therapeutics pipeline: https://ksqtx.com/pipeline/
- ClinicalTrials.gov NCT06598371: https://clinicaltrials.gov/study/NCT06598371

## Connected records

- targets: [SOCS1](https://onco.cc/targets/socs1/)
- companies: [KSQ Therapeutics](https://onco.cc/companies/ksq-therapeutics/)
- trials: [A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors](https://onco.cc/trials/nct06598371/)

---
JSON: https://onco.cc/api/v1/entities/ksq-004ex.json